APLS Relative Valuation
APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APLS is overvalued; if below, it's undervalued.
Historical Valuation
Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -26.18. The fair price of Apellis Pharmaceuticals Inc (APLS) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 25.23 USD , Apellis Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：25.23
Fair
Undervalued
-16.79
PE
1Y
3Y
5Y
Trailing
Forward
-21.01
EV/EBITDA
Apellis Pharmaceuticals Inc. (APLS) has a current EV/EBITDA of -21.01. The 5-year average EV/EBITDA is -19.53. The thresholds are as follows: Strongly Undervalued below -278.53, Undervalued between -278.53 and -149.03, Fairly Valued between 109.97 and -149.03, Overvalued between 109.97 and 239.47, and Strongly Overvalued above 239.47. The current Forward EV/EBITDA of -21.01 falls within the Historic Trend Line -Fairly Valued range.
-19.38
EV/EBIT
Apellis Pharmaceuticals Inc. (APLS) has a current EV/EBIT of -19.38. The 5-year average EV/EBIT is -58.87. The thresholds are as follows: Strongly Undervalued below -798.09, Undervalued between -798.09 and -428.48, Fairly Valued between 310.73 and -428.48, Overvalued between 310.73 and 680.34, and Strongly Overvalued above 680.34. The current Forward EV/EBIT of -19.38 falls within the Historic Trend Line -Fairly Valued range.
3.76
PS
Apellis Pharmaceuticals Inc. (APLS) has a current PS of 3.76. The 5-year average PS is 36.28. The thresholds are as follows: Strongly Undervalued below -71.25, Undervalued between -71.25 and -17.49, Fairly Valued between 90.05 and -17.49, Overvalued between 90.05 and 143.82, and Strongly Overvalued above 143.82. The current Forward PS of 3.76 falls within the Historic Trend Line -Fairly Valued range.
-95.90
P/OCF
Apellis Pharmaceuticals Inc. (APLS) has a current P/OCF of -95.90. The 5-year average P/OCF is -60.38. The thresholds are as follows: Strongly Undervalued below -350.69, Undervalued between -350.69 and -205.53, Fairly Valued between 84.77 and -205.53, Overvalued between 84.77 and 229.92, and Strongly Overvalued above 229.92. The current Forward P/OCF of -95.90 falls within the Historic Trend Line -Fairly Valued range.
161.12
P/FCF
Apellis Pharmaceuticals Inc. (APLS) has a current P/FCF of 161.12. The 5-year average P/FCF is -9.25. The thresholds are as follows: Strongly Undervalued below -133.45, Undervalued between -133.45 and -71.35, Fairly Valued between 52.84 and -71.35, Overvalued between 52.84 and 114.94, and Strongly Overvalued above 114.94. The current Forward P/FCF of 161.12 falls within the Strongly Overvalued range.
Apellis Pharmaceuticals Inc (APLS) has a current Price-to-Book (P/B) ratio of 7.87. Compared to its 3-year average P/B ratio of 20.81 , the current P/B ratio is approximately -62.18% higher. Relative to its 5-year average P/B ratio of 16.33, the current P/B ratio is about -51.79% higher. Apellis Pharmaceuticals Inc (APLS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.58%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.18% , the current FCF yield is about -100.00% lower.
7.87
P/B
Median3y
20.81
Median5y
16.33
2.52
FCF Yield
Median3y
-6.58
Median5y
-7.18
Competitors Valuation Multiple
The average P/S ratio for APLS's competitors is 4.54, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 132.98%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of APLS decreased by 20.93% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 196.83M to 458.58M.
The secondary factor is the P/E Change, contributed 107.24%to the performance.
Overall, the performance of APLS in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Apellis Pharmaceuticals Inc (APLS) currently overvalued or undervalued?
What is Apellis Pharmaceuticals Inc (APLS) fair value?
How does APLS's valuation metrics compare to the industry average?
What is the current P/B ratio for Apellis Pharmaceuticals Inc (APLS) as of Dec 13 2025?
What is the current FCF Yield for Apellis Pharmaceuticals Inc (APLS) as of Dec 13 2025?
What is the current Forward P/E ratio for Apellis Pharmaceuticals Inc (APLS) as of Dec 13 2025?